1. Introduction
The respiratory system is one of the most vital systems in the human body, responsible for oxygen uptake and carbon dioxide elimination — essential processes that sustain cellular metabolism. Pathophysiology of respiratory diseases refers to the study of functional changes that occur in the lungs and airways as a result of disease or injury. Respiratory diseases range from mild reversible conditions like asthma to severe irreversible disorders such as chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and lung cancer.
Understanding respiratory pathophysiology is crucial for diagnosing, preventing, and managing these disorders. It involves exploring the interaction between anatomy, physiology, immune responses, environmental exposures, and genetic predispositions that disrupt normal respiration.
2. Anatomy and Physiology of the Respiratory System
2.1 Structural Organization
The respiratory system is divided into two main parts:
- Upper respiratory tract: nose, nasal cavity, pharynx, and larynx.
- Lower respiratory tract: trachea, bronchi, bronchioles, and alveoli.
Air passes through the upper tract, is filtered, humidified, and warmed, then reaches the alveoli — the primary site of gas exchange.
2.2 Functional Units
- Conducting zone: transports air (from trachea to terminal bronchioles).
- Respiratory zone: includes respiratory bronchioles, alveolar ducts, and alveoli — where gas exchange occurs.
Each lung contains around 300 million alveoli, providing a surface area of about 70 square meters for gas exchange.
2.3 Physiology of Gas Exchange
Oxygen diffuses from alveoli to pulmonary capillaries, while carbon dioxide diffuses in the opposite direction. This exchange depends on:
- Partial pressure gradients (as per Fick’s Law of Diffusion)
- Alveolar surface area
- Membrane thickness
- Blood flow and ventilation matching (V/Q ratio)
2.4 Neural and Chemical Regulation
Respiration is regulated by centers in the medulla oblongata and pons, modulated by chemoreceptors that sense CO₂, O₂, and pH levels. Peripheral chemoreceptors (in carotid and aortic bodies) respond to hypoxia, while central chemoreceptors respond to changes in CO₂ and pH in cerebrospinal fluid.
3. General Pathophysiological Mechanisms of Respiratory Diseases
Respiratory pathophysiology involves several common mechanisms that lead to impaired ventilation, diffusion, and perfusion.
3.1 Inflammation
Inflammation is a central feature of most respiratory diseases. It can be acute (e.g., pneumonia) or chronic (e.g., COPD, asthma).
Inflammatory mediators such as histamine, cytokines (IL-1, TNF-α), and leukotrienes lead to:
- Vasodilation and increased permeability
- Mucosal edema
- Excess mucus production
- Airway narrowing
3.2 Hypoxia and Hypercapnia
- Hypoxia: decreased oxygen levels in tissues.
- Hypercapnia: increased CO₂ levels due to hypoventilation.
These conditions disturb acid-base balance, causing respiratory acidosis or alkalosis, which further impacts cardiac and neurological functions.
3.3 Ventilation-Perfusion (V/Q) Imbalance
Optimal gas exchange requires matching of ventilation (air reaching alveoli) and perfusion (blood flow).
- Low V/Q ratio: seen in airway obstruction, leading to hypoxia.
- High V/Q ratio: seen in pulmonary embolism, leading to wasted ventilation.
3.4 Airway Remodelling and Fibrosis
Chronic inflammation can lead to structural changes such as:
- Thickened airway walls
- Collagen deposition
- Smooth muscle hypertrophy
These changes reduce elasticity and impair airflow, common in asthma and COPD.
3.5 Immune and Allergic Responses
Overactive immune responses cause hypersensitivity and autoimmunity.
- Type I hypersensitivity (IgE-mediated) is seen in asthma.
- Type IV hypersensitivity (delayed response) occurs in tuberculosis.
4. Major Respiratory Diseases and Their Pathophysiology
4.1 Asthma
Asthma is a chronic inflammatory disease of the airways characterized by reversible airway obstruction, bronchial hyperresponsiveness, and episodic wheezing.
Pathophysiology:
- Triggered by allergens, infections, or stress.
- Mast cells release histamine and leukotrienes → bronchoconstriction.
- Infiltration by eosinophils and T-helper 2 (Th2) cells → chronic inflammation.
- Airway remodelling due to smooth muscle hypertrophy and mucus hypersecretion.
Consequences:
- Reduced expiratory airflow
- Air trapping and hyperinflation
- Hypoxemia during acute attacks
4.2 Chronic Obstructive Pulmonary Disease (COPD)
COPD includes chronic bronchitis and emphysema, characterized by irreversible airflow limitation.
Pathophysiology:
- Chronic exposure to irritants (smoke, pollutants) → neutrophilic inflammation.
- In chronic bronchitis, goblet cell hyperplasia → mucus overproduction → airway obstruction.
- In emphysema, destruction of alveolar walls → loss of elastic recoil → air trapping and hyperinflation.
Result:
- V/Q mismatch
- Hypoxia and hypercapnia
- Pulmonary hypertension → cor pulmonale (right heart failure)
4.3 Pneumonia
Pneumonia is an infection of the alveoli, commonly caused by bacteria like Streptococcus pneumoniae.
Pathophysiology:
- Pathogens enter alveoli → immune response → exudate formation.
- Alveoli fill with fluid and leukocytes → impaired gas exchange.
- Hypoxemia develops due to shunting of blood through non-aerated alveoli.
4.4 Tuberculosis (TB)
Caused by Mycobacterium tuberculosis, TB primarily affects the lungs.
Pathophysiology:
- Bacteria inhaled and engulfed by macrophages → granuloma formation.
- Central caseous necrosis surrounded by epithelioid cells and lymphocytes.
- If immune system fails, reactivation leads to cavitation and tissue destruction.
Outcome: chronic cough, hemoptysis, fibrosis, and respiratory insufficiency.
4.5 Acute Respiratory Distress Syndrome (ARDS)
ARDS is a rapid-onset respiratory failure due to alveolar-capillary damage.
Pathophysiology:
- Triggers: sepsis, trauma, or aspiration.
- Inflammatory cytokines increase capillary permeability → protein-rich edema.
- Formation of hyaline membranes → impaired gas diffusion.
- Decreased surfactant → alveolar collapse → severe hypoxemia.
4.6 Lung Cancer
A malignant transformation of bronchial epithelium due to carcinogens (mainly tobacco smoke).
Pathophysiology:
- Genetic mutations in oncogenes and tumor suppressor genes (KRAS, TP53).
- Uncontrolled cell proliferation and invasion of surrounding tissues.
- Obstruction of airways → atelectasis and infection.
- Metastasis to brain, bone, and liver.
4.7 Pulmonary Fibrosis
Characterized by excessive deposition of connective tissue in lung parenchyma.
Pathophysiology:
- Chronic injury → fibroblast proliferation → collagen accumulation.
- Thickening of alveolar walls → decreased diffusion capacity.
- Leads to restrictive lung pattern and hypoxemia.
4.8 Pulmonary Embolism
A blockage of the pulmonary artery, usually by a thrombus.
Pathophysiology:
- Embolus obstructs blood flow → high V/Q ratio.
- Increased pulmonary vascular resistance → right ventricular strain.
- Reduced perfusion → ventilation wasted → hypoxemia.
5. Interrelation of Respiratory and Systemic Pathophysiology
Respiratory diseases rarely act in isolation. Chronic hypoxia and inflammation have systemic consequences:
- Cardiovascular system: pulmonary hypertension, right heart failure.
- Renal system: hypoxia-induced erythropoietin release → polycythemia.
- Nervous system: hypercapnia → confusion, headaches.
- Metabolic system: respiratory acidosis/alkalosis alters cellular metabolism.
Thus, respiratory dysfunction can initiate or exacerbate multi-organ failure.
6. Recent Advances in Understanding Respiratory Pathophysiology
Modern research has deepened our understanding through:
- Molecular genetics: identification of genes regulating airway inflammation.
- Immunopathology: discovery of cytokine networks (IL-4, IL-5, IL-13) in asthma.
- Lung microbiome studies: showing microbial diversity influences immunity.
- Stem cell and regenerative therapies: potential to repair damaged lung tissue.
- Precision medicine: biomarkers predicting COPD exacerbations or cancer response.
7. Summary
The pathophysiology of respiratory diseases reflects complex interactions between the body’s defense systems, environmental exposures, and genetic factors. Inflammation, fibrosis, and airway remodelling are recurring pathological themes that disrupt the delicate balance of ventilation and perfusion.
Understanding these mechanisms enables healthcare professionals to target therapies more precisely — from anti-inflammatory treatments in asthma to antifibrotic agents in pulmonary fibrosis. Moreover, lifestyle interventions such as smoking cessation, pollution control, and yoga-based breath regulation can complement medical approaches, fostering respiratory resilience and overall wellbeing.